Endpoints News· Kyle LaHucik·· 3 小时前AI 评分56
Ultragenyx 裁员 20% 并放弃 Wilson 病基因疗法
Ultragenyx to lay off 20% of employees, scrap a Wilson disease gene therapy
AI 导读
Ultragenyx 宣布裁员 20%，并放弃一项 Wilson 病基因疗法。此前第三季度公司获得两项 FDA 批准，但在 Angelman 综合征项目上遭遇重大挫折，这是其第二轮裁员。
正文 · 原文
After a whirlwind third quarter that saw two FDA approvals but a major setback in Angelman syndrome, Ultragenyx is laying off staff for the second …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源：Endpoints News · endpoints.news